The Dura debate: recent Securities Litigation decisions on loss causation

The Supreme Court's decision two years ago in Dura Pharmaceutical has led to a number of key appellate rulings applying the Court's decision on loss causation. Although the Court's analysis has raised a number of interpretive issues, the appellate decisions to date reflect a decidedly strict construction of the Court's holdings, and bode well for public companies sued under the Private Securities Litigation Reform Act. [PUBLICATION ABSTRACT]